Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 31, 2022 - Issue 11
Submit an article Journal homepage
105
Views
0
CrossRef citations to date
0
Altmetric
Original Research

The effect of a single escalating dose of long-acting recombinant human follicle-stimulating hormone Fc fusion protein (KN015) on healthy, pituitary-suppressed women: first-in-human and randomized study on its pharmacokinetics, pharmacodynamics, and tolerability

Hong Zhanga Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, ChinaView further author information
,
Yanyan Fanb Department of Gynecology, The First Hospital of Jilin University, Jilin, ChinaView further author information
,
Lei Gaoa Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, ChinaView further author information
,
Boguang Wangc Corning Jeri (Jilin) Biotechnology Co., Ltd, Jilin, ChinaView further author information
,
Ting Xuc Corning Jeri (Jilin) Biotechnology Co., Ltd, Jilin, ChinaView further author information
,
Min Wua Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, ChinaView further author information
,
Jingrui Liua Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, ChinaView further author information
,
Xiaoxue Zhua Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, ChinaView further author information
,
Xiaojiao Lia Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, ChinaView further author information
,
Hong Chena Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, ChinaView further author information
,
Cuiyun Lia Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, ChinaORCID Iconhttps://orcid.org/0000-0002-6306-2394View further author information
ORCID Icon,
Meng Wanga Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, ChinaView further author information
,
Chengjiao Liua Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, ChinaView further author information
,
Yanhong Maoc Corning Jeri (Jilin) Biotechnology Co., Ltd, Jilin, ChinaView further author information
,
Mingtang Yangc Corning Jeri (Jilin) Biotechnology Co., Ltd, Jilin, ChinaView further author information
&
Yanhua Dinga Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 1255-1263 | Received 31 Jul 2022, Accepted 21 Nov 2022, Published online: 20 Dec 2022

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.